Content Search Navigation Sitemap A diversified portfolio across clinical stages Our purpose is to maximise value and transform patient outcomes. Our Investment Manager has created a portfolio of life science companies and is investing in and managing these companies to deliver key value inflection points, which have the potential to deliver significant NAV growth through M&A and liquidity events. Making a positive contribution We are committed to managing our business in a sustainable way, investing responsibly, and supporting our portfolio companies in making positive contributions to society by developing treatments that will make a difference to the lives of patients and their families. Latest news iOnctura debuts cambritaxestat (IOA-289) clinical data in patients with pancreatic cancer at ESMO Clinical companies iOnctura Resolution Therapeutics announces upcoming presentations at the American Association for the Study of Liver Disease (AASLD) The Liver Meeting® 2025 Clinical companies Resolution Therapeutics Spur Therapeutics Presents Updated Phase 1/2 Data on Its Gene Therapy Candidate in Gaucher Disease at ESGCT 32nd Annual Congress Late-stage clinical companies Spur Therapeutics Resolution Therapeutics to present EMERALD study design at the British Association for the Study of the Liver (BASL) annual meeting 2025 Clinical companies Resolution Therapeutics Yellowstone Biosciences Appoints James (“Jim”) MacDonald as Chief Executive Officer Pre-clinical companies Yellowstone Biosciences Resolution Therapeutics appoints Lucy Singah as Chief Financial Officer and Daniel Kennedy as Chief Business Officer Clinical companies Resolution Therapeutics iOnctura Expands Roginolisib Trials to the US, Advancing Multi-Indication Strategy in Oncology Clinical companies iOnctura Resolution Therapeutics announces first patient dosed in Phase I/II EMERALD study of RTX001 for the treatment of end-stage liver disease Clinical companies Resolution Therapeutics OMass Therapeutics Enters into Exclusive Collaboration and License Agreement with Genentech to Develop and Commercialize Therapies for Inflammatory Bowel Disease Pre-clinical companies OMass Therapeutics Resolution Therapeutics to host virtual R&D webinar alongside world leading clinical hepatologists Prof. Jonathan Fallowfield and Dr. Elliot Tapper Clinical companies Resolution Therapeutics OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee Pre-clinical companies OMass Therapeutics Purespring Therapeutics receives UK CTA approval for Phase I/II clinical trial of PS-002 in patients with primary IgA nephropathy (IgAN) Pre-clinical companies Purespring Therapeutics OMass Therapeutics Presents Positive Preclinical Data For its Best-in-class MC2 Program at ENDO 2025 Pre-clinical companies OMass Therapeutics Beacon Therapeutics completes enrolment in registrational Phase 2/3 VISTA trial of laru-zova for patients with XLRP Purespring Therapeutics announce FDA IND clearance for Phase I/II clinical trial for primary IgA nephropathy (IgAN) Pre-clinical companies Purespring Therapeutics OMass Therapeutics to Present New Preclinical Data For its Best-in-Class MC2 Program at ENDO 2025 Pre-clinical companies OMass Therapeutics Northern Gritstone invests in Manchester spinout Apini Quell Therapeutics Achieves Key Milestone in its CAR-Treg Cell Therapy Program for Inflammatory Bowel Disease Clinical companies Quell Therapeutics 2025 Annual Report Our Annual Report and Accounts 2025 provides an overview of our strategy update as we seek to maximise value for shareholders. An expert multi-disciplinary team, attracting world-class talent We are differentiated by our people, who identify innovative technology and take a commercial approach to building businesses capable of delivering transformational treatments to patients. About View this section View this section Who we are NAV Growth Framework View this section View this section Who we are NAV Growth Framework Our people View this section View this section Board of Directors View this section View this section Board of Directors Portfolio View this section View this section Commercial companies Overview Autolus Therapeutics Late-stage clinical companies Overview Beacon Therapeutics Spur Therapeutics Clinical companies Overview iOnctura Quell Therapeutics Anaveon Mosaic Therapeutics Resolution Therapeutics Pre-clinical companies Overview Purespring Therapeutics Forcefield Therapeutics OMass Therapeutics Kesmalea Therapeutics Yellowstone Biosciences Slingshot Therapeutics Previous portfolio companies Overview Gyroscope Therapeutics Blue Earth Nightstar Neogene Therapeutics 14MG Azeria Therapeutics Clade Therapeutics View this section View this section Commercial companies Overview Autolus Therapeutics Overview Autolus Therapeutics Late-stage clinical companies Overview Beacon Therapeutics Spur Therapeutics Overview Beacon Therapeutics Spur Therapeutics Clinical companies Overview iOnctura Quell Therapeutics Anaveon Mosaic Therapeutics Resolution Therapeutics Overview iOnctura Quell Therapeutics Anaveon Mosaic Therapeutics Resolution Therapeutics Pre-clinical companies Overview Purespring Therapeutics Forcefield Therapeutics OMass Therapeutics Kesmalea Therapeutics Yellowstone Biosciences Slingshot Therapeutics Overview Purespring Therapeutics Forcefield Therapeutics OMass Therapeutics Kesmalea Therapeutics Yellowstone Biosciences Slingshot Therapeutics Previous portfolio companies Overview Gyroscope Therapeutics Blue Earth Nightstar Neogene Therapeutics 14MG Azeria Therapeutics Clade Therapeutics Overview Gyroscope Therapeutics Blue Earth Nightstar Neogene Therapeutics 14MG Azeria Therapeutics Clade Therapeutics Sustainability View this section View this section Our approach to sustainability reporting Syncona Fellowship Sustainability policies View this section View this section Our approach to sustainability reporting Syncona Fellowship Sustainability policies The Foundation News & insights View this section View this section News Insights & articles Publications & presentations View this section View this section News Insights & articles Publications & presentations Investors View this section View this section Results and presentations RNS and inside information Share price centre Governance Our Committees Financial calendar Events calendar Analysts and advisers Shareholder information Overview Regulatory publications Shareholder documents FAQs View this section View this section Results and presentations RNS and inside information Share price centre Governance Our Committees Financial calendar Events calendar Analysts and advisers Shareholder information Overview Regulatory publications Shareholder documents Overview Regulatory publications Shareholder documents FAQs Contact Search